AUAUniversity

AUA2025: Should I Order a PET Scan? Integrating Molecular Imaging Into Urologic Oncology Clinical Practice: Current Approaches and Future Opportunities

CME Available: https://auau.auanet.org/node/43003

At the conclusion of this activity, participants will be able to:

1. Analyze the best available evidence on the current diagnostic imaging options for prostate, kidney, bladder, and testis cancer detection, staging, and follow-up.

2. Identify the benefits of combined functional and anatomic information gained through accurate matching of anatomic (CT/MRI) and functional (PET) images

3. Debate the strengths and limitations of emerging molecular imaging techniques compared to existing diagnostic tests.

4. Optimally stage urologic oncology patients by understanding the performance characteristics of standard and emerging molecular imaging modalities.

5. Identify the emerging role of PET imaging and novel radiotracers to assess chemotherapy and immunotherapy response.

6. Formulate a strategic plan for appropriate integration of molecular imaging into clinical practice.

ACKNOWLEDGEMENTS:

This educational activity is supported by independent educational grants from:

Astellas, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Lantheus Medical Imaging, Novartis Pharmaceuticals Corporation, Pfizer, Inc.

AUA2025: AUA Guidelines on Early Detection of Prostate Cancer: Maximizing Benefits, Minimizing Harm

CME Available: https://auau.auanet.org/node/43021

At the conclusion of this activity, participants will be able to:

1. Apply the Early Detection of Prostate Cancer: AUA/SUO Guideline (2023), and understand the rationale, evidence, level of evidence, strength of recommendation and applications associated with each statement.

2. Maximize the benefits and minimize the harms of prostate cancer detection by carefully selecting patients and by using the necessary tools to detect clinically significant prostate cancer, while avoiding unnecessary biopsies and detection of clinically insignificant prostate cancers.

3. Describe the evidence supporting the use of PSA for early detection of prostate cancer, and apply that evidence to different clinical scenarios, incorporating patient characteristics and preferences.

4. Identify available blood, urine and tissue biomarkers used to enhance detection of higher-grade prostate cancer, the evidence supporting their use, and the clinical scenarios in which they are most valuable to be used.

5. Use MRI and fusion biopsy to enhance the detection of clinically significant prostate cancer and implement safe biopsy practices with respect to approach, avoidance of infection, and attention to patient comfort; understand the rationale for transperineal prostate biopsy and its technique; be able to establish a transperineal biopsy practice.

ACKNOWLEDGEMENTS:

This educational activity is supported by independent educational grants from:

Astellas, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Lantheus Medical Imaging, Novartis Pharmaceuticals Corporation, Pfizer, Inc.

AUA2025: Genetics and Genomics of Urological Cancers - Current Guidelines and Case-based Discussion to Guide Clinical Practice

CME Available: https://auau.auanet.org/node/43015

At the conclusion of this activity, participants will be able to:

1. Describe key components of genetic risk assessment, genetic counseling, and informed consent for genetic testing.

2. Describe elements of genetic test reports including variant classification, variant allele frequency, gene penetrance, biomarkers, and clinical actionability.

3. Identify criteria for genetic testing for men with prostate cancer. Understand the clinical implications of genetic results in prostate cancer screening and management of both localized and advanced prostate cancer.

4. Describe genetic causes, clinical manifestations, indication for genetic testing, and cancer risk associated with hereditary kidney cancer syndromes. Understand how genetic mutation can guide targeted therapy in patients with von Hippel-Lindau syndrome.

5. Recognize genetic causes, tumor features, and cancer risk associated with Lynch syndrome and apply gained knowledge to improve care of patients with upper tract urothelial carcinoma.

ACKNOWLEDGEMENTS:

This educational activity is supported by independent educational grants from:

Astellas, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Lantheus Medical Imaging, Novartis Pharmaceuticals Corporation, Pfizer, Inc.

Highlights from AUA2025: Advances in NMIBC (2025)

CME Available: https://auau.auanet.org/node/43167

At the conclusion of this CME activity, participants will be able to:

1. Recognize recent developments in the management of NMIBC.

2. Evaluate new and emerging therapies for NMIBC, such as novel intravesical agents and immunotherapies, their mechanism of action and related adverse events.

3. Employ current management approaches for NMIBC.

4. Utilize risk stratification to guide treatment decisions for NMIBC patients.

5. Implement diagnostic techniques for NMIBC, including cystoscopy, urine cytology, biomarkers, and advanced imaging modalities.

This educational activity is supported by independent educational grants from:

Merck & Co., Inc.

ImmunityBio, Inc.

AUA Guidelines: Microhematuria

Co-Hosts: Daniel A. Barocas, MD, MPH & Stephen Boorjian, MD

Microhematuria: AUA/SUFU Guideline (2025)

Barocas DA, Lotan Y, Matulewicz RS, Raman JD, Westerman ME, Kirkby E, Pak L, Souter L. Updates to Microhematuria: AUA/SUFU Guideline (2025). J Urol. 0(0). doi: 10.1097/JU.0000000000004490. https://www.auajournals.org/doi/abs/10.1097/JU.0000000000004490

AUA2025: Embracing Multi-Disciplinary Care for Advanced Prostate Cancer: A Case-Based Update 2025

CME Available: https://auau.auanet.org/node/42997

At the conclusion of this activity, participants will be able to:

1. Initial Management of Metastatic Prostate Cancer: Evaluate and treat a patient with new diagnosed M1 prostate cancer with androgen deprivation therapy (ADT) plus be skilled to offer novel oral antiandrogens. Furthermore, to recognize high-volume new M1 prostate cancer so as to be able to partner with GU medical oncologist for docetaxel chemotherapy in a multidisciplinary team.

2. Non-Metastatic Castrate Resistant Prostate Cancer (M0 CRPC): The learner will be skilled to diagnose M0 CRPC and be able to educate patients about using either enzalutamide or apalutamide or darolutamide added to traditional ADT as a way to improve their patent's overall and radiographic progression-free survival. Furthermore, the skilled learner will be able to understand the differences between these three oral agents and to educate patients about side-effects and toxicities. Finally, understand the pros and cons of PSMA PET scan imaging in further staging in this disease Non-metastatic Castrate-Resistant Prostate Cancer (M0 CRPC): Diagnose M0 CRPC and be able to educate patients about using novel oral antiandrogens added to traditional ADT as a way to improve their patent's overall and radiographic progression-free survival. Furthermore, the skilled learner will be able to understand the differences between these novel oral agents and to educate patients about side effects and toxicities. Finally, understand the pros and cons of PSMA PET scan imaging in further staging in this disease state.

3. Metastatic Castrate-Resistant Prostate Cancer (M1 CRPC): Describe and have a working knowledge of the latest phase III RCT results for new therapies in M1 CRPC and be able to educate their patients on treatment options and participate in a multidisciplinary team caring for men with this disease state of far-advanced prostate cancer.

4. Describe that advanced prostate cancer is a complex group of disease states with an ever-changing therapeutic landscape and for providers and teams to embrace the multi-disciplinary nature of care for our patients.

5. Identify the molecular and molecular genetic underpinnings of advanced prostate cancer and recognize the future will be based on a more personalized therapy landscape including PARP inhibition, immune checkpoint agents, and novel AR targeted agents emerging in 2025 and beyond.

AUA2025: Non-Muscle Invasive Bladder Cancer Treatment Dilemmas: The Cases You Face and How Best to Treat Them

CME Available: https://auau.auanet.org/node/43041

At the conclusion of this activity, participants will be able to:

1. Confidently apply updated guidelines to the care of patients with non-muscle-invasive bladder cancer.

2. Risk-stratify patients with non muscle- invasive bladder cancer.

3. Adapt treatment choices depending on risk of disease, including consideration to the availability of bacillus Calmette-Guérin.

4. Counsel and manage patients with bacillus Calmette-Guérin-unresponsive non muscle-invasive bladder cancer, including treatment selection with newly approved agents for BCG-unresponsive disease.

5. Individualize patient surveillance according to risk stratification.

6. Evaluate available urinary bladder cancer biomarkers and where to potentially utilize them in practice to inform management.

ACKNOWLEDGEMENTS

This educational activity is supported by an independent educational grants from:

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

AUA2025: Integration of Biomarkers, MRI and PSMA PET Imaging Into the Management of Prostate Cancer

CME Available: https://auau.auanet.org/node/43069

At the conclusion of this CME activity, participants will be able to:

1. Evaluate recent advances in biomarkers and molecular imaging technologies and their role in improving the accuracy of prostate cancer staging, and treatment monitoring.

2. Identify the clinical scenario in which PSMA PET/CT is most helpful to identify the localization and extent of locoregional or systemic metastatic disease.

3. Identify the pitfalls of false-positive and false-negative PSMA PET/CT findings.

4. Apply the findings of PSMA PET/CT for the best individual therapeutic approach.

5. Identify patients with radiorecurrent organ-confined prostate cancer.

ACKNOWLEDGEMENTS

Support provided by independent educational grants from:

Blue Earth Diagnostics, Inc.

Lantheus Medical Imaging

Novartis Pharmaceuticals Corporation

AUA2025: PARP-Inhibitor Combination Treatments for the Urologic Care Team

CME Available: https://auau.auanet.org/node/42822

At the conclusion of this CME activity, participants will be able to:

1. Apply the mechanism of action of PARP inhibitors and the rationale for using them in patients with advanced prostate cancer.

2. Recognize the role and importance of genetic testing in patients with mCRPC and the implications of germline mutations on response to therapy.

3. Identify best practices and utilize available guidelines for patients with mCRPC to optimize treatment success and oncologic outcomes.

4. Recognize when to use PARP inhibitors as monotherapy, the rationale and indications for combination therapy, and appropriate treatment sequencing.

5. Successfully counsel patients on the possible adverse events associated with PARP inhibitor therapies alone or in combination.

ACKOWLEDGEMENTS

Support provided by independent educational grants from:

AstraZeneca

Merck & Co., Inc.

Live from AUA2025: Advances in ADT Program

CME Available: https://auau.auanet.org/content/LiveFromAUA2025#group-tabs-node-course-default1

ACKNOWLEDGEMENTS:

This educational activity is supported by independent educational grants from:

Pfizer, Inc.

Sumitomo Pharma America, Inc.

At the conclusion of this CME activity, participants will be able to:

1. Employ the latest AUA and NCCN guidelines (Version 1.2025) related to Androgen Deprivation Therapy (ADT) into practice

2. Evaluate clinical outcomes, efficacy, and safety profiles of different types of ADT including oral and parenteral LHRH agonists and GnRH receptor antagonists in different treatment settings.

3. Compare testosterone recovery, treatment efficacy, safety profiles, and patient preferences between different modalities of ADT.

4. Recognize common side effects associated with different types of ADT and its combination therapies as well as strategies to mitigate these adverse effects to improve patient outcomes.

5. Implement a multi-disciplinary approach in managing advanced prostate cancer with ADT.

6. Evaluate the future directions and ongoing research that may impact the use of ADT in clinical practice.